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Abstract: DNA repair deficiencies and genome instability are common features and hallmarks of cancer
and are ubiquitously found in the full spectrum of malignant diseases. Heritable DNA repair deficiencies,
for example, due to BRCA1 and BRCA2 mutations, and subsequent loss of heterozygosity in mammary,
ovarian, and prostate carcinoma, are risk factors for the early development of cancer. Despite their detri-
mental role in tumorigenesis, these deficiencies also provide novel opportunities for treatment options.
Current and future pharmacologic approaches in medical oncology rely on the exploitation of such ge-
netically defined, tumor-specific Achilles’ heels and integrate the genetic background of a tumor into the
treatment strategy. For example, homologous recombination–corrupted, BRCA1/2-mutated tumors are
becoming hypersensitive to inhibitors of an additional DNA-damage-repair mechanism and are success-
fully treated with respective molecular targeting agents such as PARP1 inhibitors. Patient stratification
in radiation oncology today is primarily based on clinical parameters and uses highly sophisticated di-
agnostic imaging for treatment planning on the individual level. Radiation oncology only minimally
takes the genetic makeup of tumors into account, and little attention has been given to the fact that
the different modalities of ionizing radiation, such as photon and proton irradiation, may also induce
differential damages and biological processes, which might again be influenced by the genetic makeup
and mutational status of the tumor. However, radiation oncology is nowadays challenged to understand
subtle differences induced by the different qualities of ionizing radiation, and to efficiently exploit and to
integrate these differential responses in a personalized treatment approach alone and as part of combined
treatment modalities with pharmacologic agents. Here we will review recent insights on the differential
DNA damage responses to photon and proton irradiation and discuss their implications for combined
treatment modalities with chemotherapeutical agents and small molecular targeting compounds.
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Abstract
DNA repair deficiencies and genome instability are common features and hallmarks of
cancer and are ubiquitously found in the full spectrum of malignant diseases. Heritable
DNA repair deficiencies, for example, due to BRCA1 and BRCA2 mutations, and
subsequent loss of heterozygosity in mammary, ovarian, and prostate carcinoma, are
risk factors for the early development of cancer. Despite their detrimental role in
tumorigenesis, these deficiencies also provide novel opportunities for treatment options.
Current and future pharmacologic approaches in medical oncology rely on the
exploitation of such genetically defined, tumor-specific Achilles’ heels and integrate the
genetic background of a tumor into the treatment strategy. For example, homologous
recombination–corrupted, BRCA1/2-mutated tumors are becoming hypersensitive to
inhibitors of an additional DNA-damage-repair mechanism and are successfully treated
with respective molecular targeting agents such as PARP1 inhibitors.
Patient stratification in radiation oncology today is primarily based on clinical parameters
and uses highly sophisticated diagnostic imaging for treatment planning on the individual
level. Radiation oncology only minimally takes the genetic makeup of tumors into
account, and little attention has been given to the fact that the different modalities of
ionizing radiation, such as photon and proton irradiation, may also induce differential
damages and biological processes, which might again be influenced by the genetic
makeup and mutational status of the tumor. However, radiation oncology is nowadays
challenged to understand subtle differences induced by the different qualities of ionizing
radiation, and to efficiently exploit and to integrate these differential responses in a
personalized treatment approach alone and as part of combined treatment modalities
with pharmacologic agents. Here we will review recent insights on the differential DNA
damage responses to photon and proton irradiation and discuss their implications for
combined treatment modalities with chemotherapeutical agents and small molecular
targeting compounds.
Keywords: proton irradiation; combined treatment modality DNA damage response;
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Introduction
Approximately 50% of all cancer patients have an indication for radiation therapy at least
once during the course of their disease, with an absolute number of patients steadily
increasing assuming overall cancer rates remain unchanged ([Borras et al [1] and
http://theijpt.org
references therein). The main pillar of radiotherapy is photon irradiation with linear accelerators as source of ionizing radiation.
Nevertheless, charged-particle–based approaches such as proton or carbon beams are stepping out of their niche and are
becoming a reasonable alternative [2–4]. The high-dose deposition at the distal end followed by a steep decline as well as
minimal lateral scattering allows superior tissue sparing and a dose reduction outside the planned margin [5]. The reduced
volume of healthy tissue exposed to intermediate and low doses suggests a reduced risk of secondary malignancies
accompanied by a reduced co-irradiation of dose-limiting organs-at-risk such as brain stem, spinal cord, oral cavity, or the optic
nerve [6, 7]. Hence, current treatment decisions for particle beam therapy are primarily based on vulnerable tumor locations
near organs-at-risk, and treated entities comprise uveal melanoma, skull-based and intracranial tumors, prostate and head
and neck tumors [8, 9]. Moreover, the most common solid tumors in pediatric patients arise in the central nervous system [10]
and a long life expectance after treatment becomes aggravated by minimal safety margins in a delicate developmental stage.
Since pediatric patients are prone to impaired brain development as well as progressive cognitive decline after conventional
cranial radiation therapy, particle beam treatment emerges as a beneficial tool to reduce side effects in adult and especially in
pediatric patients [11, 12].
Proton radiation therapy is characterized by its advantageous dose deposition and physics attributes, thereby taking
primarily clinical aspects for treatment stratification into consideration. Preclinical experiments revealed an enhanced efficacy
for proton versus photon irradiation. However, the cause for this increased efficacy is insufficiently known and differential
biological stress responses induced by photon-based and particle-based irradiation are minimally investigated so far [13].
Differential ‘‘biologies’’ induced by the different sources of ionizing radiation may become relevant for the determination of
optimal therapeutic strategies and be important for the concept of personalized medicine. It may allow adapting the therapy of
an individual patient situation, taking both clinical and physical but also biological parameters into account.
Here we will provide an overview on recent preclinical insights on the differential DNA damage responses to photon and
proton irradiation and their implications for combined treatment modalities with chemotherapeutical agents and small
molecular targeting compounds.
Differential Biological Responses to Photon and Proton Irradiation
Intense preclinical in vitro and in vivo studies comparing photon and proton irradiation have illustrated differing relative
biological effectiveness (RBEs) in dependence of endpoint, tissue, and positioning in the spread-out Bragg peak (SOBP) [14–
17]. RBE deviations result from and clearly point to differential physicochemical and subsequent differential responses on the
molecular and cellular level to photon versus proton irradiation. For example, faster production of reactive oxygen species [18]
and enhanced levels of cell apoptosis [19] were identified after irradiation with low linear energy transfer (LET) proton
irradiation in comparison to photon irradiation. Furthermore, differential gene expression in response to the 2 modalities of
irradiation and increasing RBEs of cell killing along the axis of an SOBP also suggest different mechanisms being induced by
photon and proton irradiation, which could be exploited as part of a combined treatment modality [20, 21]. These preclinical
insights contrast with the generic constant RBE of 1.1 still applied in clinical practice [13, 22].
Exploitation of Differential DNA Repair Dependences
Genetically defined Chinese hamster ovary (CHO) cell lines with defects in different DNA repair systems were originally used
to identify and characterize DNA double-strand break (DSB) machineries relevant for the repair of photon irradiation–induced
DNA damage. These cell lines are interesting tools to characterize differential DNA damage responses and dependencies for
specific DNA repair machineries in response to different qualities of ionizing radiation [23–25].
Cells have evolved 2 major DSB repair pathways, namely, the more error-prone nonhomologous end joining (NHEJ)
process and homologous recombination repair (HRR) [26]. NHEJ is active throughout the cell cycle and is responsible for the
repair of most ionizing radiation–induced DSBs in eukaryotic cells. Although very efficient in a quantitative way, the quality of
repair by NHEJ can steadily decrease with increasing amounts of DNA damage [27].
Double-strand break repair by NHEJ relies on the initial binding of the Ku70/80 heterodimer, which results in the recruitment
of DNA-dependent protein kinase, catalytic subunit, also known as DNA-PKcs. If required, specialized DNA nucleases and
polymerases process the ‘‘dirty’’ ends before relegation of the broken strands by XRCC4–DNA ligase IV complex. HRR is
initiated through the recognition of DSBs by the MRN complex followed by MRN- and CtIP-dependent 30-50 DNA resection
[28]. The resulting single-stranded DNA (ssDNA) overhangs are first stabilized by the heterotrimeric ssDNA-binding complex
RPA, which is later on replaced by Rad51 with the help of BRCA2. Rad51 nucleoprotein filaments then search for homology
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and form Holliday junctions when complementary sequences are found. After ideally error-free rewriting of the damaged DNA
site by DNA polymerases, these structures get resolved by several Holliday junction processing factors, including Rad51C-
XRCC3 complex [29–31].
Detection and quantification of ionizing radiation–induced and subsequently repaired DNA DSBs represent major
challenges in experimental radiobiology. Ideally, several complementary approaches should be combined that include both
direct determination of DNA damage at the molecular level, including chromosomal aberrations, and indirect DNA damage–
related signaling readouts, which are more easily detectable, such as cH2AX foci. Phosphorylation of the histone variant H2AX
has become a powerful tool to monitor DNA DSBs induced by ionizing radiation and was named cH2AX because it was first
observed in cells exposed to c-rays [32]. Large numbers of cH2AX molecules form at the site of DNA breaks and create bright
foci that allow detection of individual DSBs. Thereby cH2AX foci can be easily counted by using specific antibodies. cH2AX
foci counting has become a major experimental readout in basic and translational radiobiology to probe induction and repair of
DNA DSBs at different time points following irradiation. Nevertheless, it only remains an indirect biomarker for DNA DSBs [33].
Using this set of CHO cells with defects in either the NHEJ (XR-C1; DNA-PKcs–deficient CHO cells) or HRR
machinery (XRCC3/), our own group recently demonstrated differential DNA repair pathway choices in response to
photon and proton irradiation. To avoid additional influences due to increasing LETs across the SOBP, cells were always
irradiated in the middle of an SOBP with a length of 5 cm and a maximum proton energy of 138 MeV (Center for Proton
Therapy at the Paul Scherrer Institute, PSI-Villigen, Switzerland) [34]. The formation of so-called cH2AX foci at the site of
DSBs was used to quantify irradiation-induced DSBs. No significant differences in the number of DNA DSBs induced by
the 2 types of irradiation could be detected; however, the repair kinetics in XRCC3-lacking cells were clearly delayed after
proton irradiation with elevated numbers of residual cH2AX foci after irradiation. Additionally, the HRR-defective cells
proved to be markedly hypersensitive to proton irradiation, resulting in an increased RBE in comparison to the RBE
determined in wild-type cells. The RBE (survival fraction as endpoint) increased from RBE37%: 1.25 6 0.05 and RBE10%:
1.29 6 0.04 in the wild-type cells to RBE37%: 1.54 6 0.10 and RBE10%: 1.44 6 0.06 in the HRR-deficient cells. While
DNA-PKcs–defective cells were overall more sensitive to both types of ionizing radiation than wild-type cells, defective
DNA-PKcs did not result in hypersensitivity towards proton irradiation. Even though these quantitative readouts were only
correlated with the cH2AX-foci assay, these results indicate a differential quality of DNA damage by proton versus photon
irradiation with a specific requirement for HRR for efficient DNA repair and enhanced cell survival in response to low LET
proton irradiation. Interestingly, differential patterns of chromosomal aberrations were also identified in response to the 2
types of ionizing radiation and in dependence of the HRR status. Of note, lack of NHEJ activity in genetically defined
knockout mouse embryo fibroblasts was shown to play the more important role for cell survival in response to high LET
irradiation than to photon irradiation and thus, targeting of NHEJ might preferentially sensitize to high LET irradiation [35].
A differential response and involvement of the 2 major DNA DSB machineries in dependence of high versus low LET
radiation might be further affected by the mutational status of the targeted cells and additional DNA DSB repair backup
mechanisms, such as alternative or B-NHEJ [36].
HRR dependence for proton irradiation–induced DNA damage was also tested in established cancer cell lines. Interestingly
and in contrast to their wild-type counterpart cell line, ovarian carcinoma cells lacking intact BRCA2 expression were also
hypersensitive towards proton in comparison to photon irradiation, which corroborated this hypothesis originally tested in the
CHO-based model cell system. Likewise, A549 non-small cell lung cancer cells depleted of the HRR essential protein Rad51
were clearly hypersensitive to proton irradiation in comparison to control cells [37]. Rad51 downregulation also induced a
tremendous delay in cH2AX-foci repair kinetics. As such, a preference of proton-induced DNA damage towards HRR might
become relevant for clinical stratification of patients carrying mutations in this DNA repair pathway.
Combined Treatment Modalities with HRR-Interfering Agents
Likewise, a state of corrupted HRR activity and thus enhanced sensitivity towards proton irradiation could be achieved by a
combined treatment modality with specific inhibitors of HRR. Direct pharmacologic targeting of the HRR machinery has proven
to be largely unsuccessful in the past years. However, several chemotherapeutic agents exist, which eventually downregulate
Rad51 protein levels—including the broad-range clinically relevant histone deacetylase inhibitor SAHA (Vorinostat) [38]—and
thereby also reduce HRR. Low dose exposure to SAHA for 24 hours was sufficient to reduce Rad51 levels down to
approximately 10% of the basal level, without affecting critical elements of NHEJ such as Ku80 or DNA-PKcs protein levels.
Similar to the results obtained in the tumor cells with a corrupted HRR machinery, DNA repair was also strongly delayed in
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SAHA-pretreated cells after proton irradiation, but only minimally after photon irradiation, corroborating this HRR-oriented
mechanism of action of SAHA.
Recently, Gerelchuluun et al [39] investigated SAHA-based radiosensitization in lung carcinoma and normal human
fibroblasts irradiated with photon, low LET proton, and carbon ion–based irradiation. SAHA sensitized to low LET radiation to a
greater extent than to carbon ion–based irradiation and even more so to proton irradiation at low SAHA concentrations. Even
though they could not directly link their results to HRR, SAHA also delayed DNA repair kinetics. More important, SAHA-
induced radiosensitization was not prominent in normal fibroblasts, which suggests a selective cancer cell–related
mechanism, of interest towards an enhanced therapeutic window.
Complementary experiments were performed with pharmacologic agents selectively inhibiting NHEJ. Interestingly, the
DNA-PKCs inhibitor NU7026 sensitized lung carcinoma and glioblastoma cells in response to both types of irradiation, yet
to a higher extent for photon irradiation, with a dose modifying factor at 10% survival (DMF10) of 1.91 6 0.05, than for
proton radiation (1.49 6 0.06) for lung and with a DMF10 of 1.49 6 0.02 versus 1.2 6 0.11 for the glioblastoma cells.
Strikingly, NU7026 treatment only minimally interfered with repair of proton-induced DNA damage, while more than half of
cH2AX foci remained unrepaired after 24 hours in the photon-irradiated cells [37]. Thus, while inhibitors of NHEJ more
specifically sensitize to photon irradiation, pharmacologic agents that directly downregulate the DNA repair capacity of
HRR might more specifically sensitize to proton irradiation.
An RBE-oriented lung cancer cell line screen performed by Liu et al [40] (research group of Henning Willers at
Massachusetts General Hospital, Boston) also linked defects in a specific DNA-damage-repair machinery to hypersensitivity to
proton irradiation [40]. A selection of NSCLC cell lines was irradiated in the middle of an SOBP, and in 3 of 17 cell lines an
increased RBE could be linked to alterations of the Fanconi anemia (FA)/BRCA pathway of DNA repair, which is part of
replication-coupled HRR [40]. Control experiments performed in wild-type and FANCD2-depleted but otherwise isogenic lung
cancer cells validated the relevance of this pathway and also supported the hypothesis of specific proton hypersensitivity due
to HRR defects. Furthermore, the role of FA/BRCA pathway in hypersensitization against proton irradiation was further backed
up by the same group focusing on 2 additional downstream elements of this pathway, namely, Slx4(FancP) and Mus81 [41].
Slx4- and Mus81-deficient cells also demonstrated enhanced sensitivity towards proton irradiation as compared to their
isogenic wild-type counterpart cells. As such, genomic profiling of DNA damage repair–associated genes might become
relevant in the future for clinical stratification of patients and be part of personalized biology-adapted treatment regimens.
DNA damage can be traced in vitro and ex vivo by the generation of so-called foci, which represent specific protein
aggregates at the site of DSBs. Interestingly, these studies also revealed that proton irradiation– and photon irradiation–
induced foci exhibit a different size, in particular in dependence of the HRR status. As suggested, DNA repair–associated
foci could therefore be used as functional biomarker to identify repair-defective and proton irradiation hypersensitive
tumors [40, 42]. It will be of interest to determine the phenotype of proton-induced foci in genetically HRR intact cancer
cells but cotreated with HRR-directed pharmaceutical inhibitors. A large amount of data and calculations on DNA damage
in response to particle irradiation exist, which are derived from different sources of ionizing radiation and which have been
incorporated into relevant modeling studies [43, 44]. However, we have only limited experimental data on differential DNA
damage, which were obtained in parallel in the same genetically defined cell systems with specific DNA damage repair
deficiencies, and which were induced by clinically relevant proton and photon irradiation. The initial amount of DSBs per
physical dose of proton irradiation is similar to the number of lesions caused by the same dose of photon irradiation,
based on the initial formation of cH2AX foci [34, 37]. However, proton irradiation might cause slightly more complex
clustered DNA damage, which is most probably due to the slightly increased LET values even in the middle of the SOBP.
While DNA DSB-proficient cells repair these damages equally well, FA/BRCA pathway– and thus replication-coupled
HRR-corrupted cells encounter greater difficulties in repairing replication forks that collide with clustered proton damage.
Eventually, impaired repair in these mutated tumor cells will translate into a hypersensitivity towards proton irradiation. As
such, the genetic status could make tumors more susceptible to proton radiation therapy and could contribute to the
definition of a variable instead of a generic RBE [45].
Similar to SAHA, other clinically relevant pharmaceutical agents and compounds in early developmental stage exist,
which directly or indirectly reduce HRR activity and have been tested in combination with photon irradiation. For example,
Gleevec (Novartis Pharma, Switzerland), which is used to treat chronic myelogenous leukemia, gastrointestinal stromal
tumors, and a number of other malignancies, also reduces RAD51 and sensitizes for ionizing radiation [46]. Likewise,
inhibitors of the hepatocyte growth factor receptor MET (mesenchymal-epithelial transition), which is overexpressed in
numerous types of human tumors and considered a prime target in clinical oncology, sensitize for ionizing radiation via
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reduced formation of the RAD51-BRCA2 complex [47]. Even classic chemotherapeutic agents like gemcitabine, which are
clinically applied in combination with radiation therapy, sensitize via selective targeting of HRR [48]. As such, treatment
combinations with agents cotargeting HRR might require a reduced dose of proton radiation to achieve the same
treatment outcome as with photon irradiation. On the other hand, agents targeting NHEJ might be less effective in
combination with proton irradiation. Most combined treatment modalities have been investigated with photon irradiation. It
will be now important to qualitatively as well as quantitatively determine the differential outcome combining these agents
also with clinically relevant proton irradiation.
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